Breaking News Instant updates and real-time market news.

ACOR

Acorda Therapeutics

$21.30

0.05 (0.24%)

06:05
11/21/16
11/21
06:05
11/21/16
06:05

Acorda Therapeutics to discontinue development of dalfampridine

Acorda Therapeutics announced that the MILESTONE clinical study did not show sufficient efficacy to support further development of dalfampridine to improve post-stroke walking difficulties. "We are disappointed by this outcome. The study indicated there was activity related to walking in people with PSWD, as suggested by the prior Phase 2 study, but overall this was not sufficiently clinically meaningful. I want to express our gratitude to the study participants, their care partners and clinicians, who gave their time and commitment to this research," said Ron Cohen, M.D., President and CEO of Acorda. "This outcome underscores the risks that companies in the biopharmaceutical industry must take in order to develop innovative medicines. Over the past three years, we have successfully diversified our pipeline portfolio to account for this risk. We plan to focus R&D resources on developing our promising late-stage Parkinson's disease therapies, CVT-301 and tozadenant, as well as advancing our earlier stage assets, CVT-427 in migraine, SYN120 in Parkinson's disease dementia, and rHIgM22 in MS." As part of the PSWD development program, a multi-dose pharmacokinetic study confirmed the Company has developed a potentially viable once-daily formulation of dalfampridine. The Company elected to stop enrollment and to conduct an unblinded analysis of the MILESTONE trial after reaching enrollment of 377 participants. This analysis included 368 participants who received either 10 mg or 7.5 mg of dalfampridine twice daily or placebo. The primary outcome measure of the study was the proportion of participants who showed at least a 20% improvement on the Two Minute Walk Test at Week 12 as compared to baseline. The 2MinWT measures the distance a subject can walk in 2 minutes, and is a validated scale used to assess walking capacity. The study found that 23 of 121 (19.0%) participants receiving 10 mg of dalfampridine BID and 17 of 121 (14.0%) participants receiving 7.5 mg of dalfampridine BID showed at least a 20% improvement on the 2MinWT, compared to 17 of 126 (13.5%) participants receiving placebo. In this study, dalfampridine was well tolerated in the post-stroke population. The safety profile overall was similar to that observed in multiple sclerosis clinical trials and post-marketing surveillance. The most common adverse events (greater than or equal to 5%) reported in this study were: falls (10 mg: 10.7%, 7.5 mg: 9.5%, placebo: 5.6%), urinary tract infections (10 mg: 9.0%, 7.5 mg: 6.3%, placebo: 2.4%), dizziness (10 mg: 3.3%, 7.5 mg: 7.9%, placebo: 2.4%) and fatigue (10mg: 2.5%, 7.5 mg: 3.2%, placebo: 6.3%). There were no seizures reported in the dalfampridine 10 mg group. There were 2 seizures reported in the 7.5 mg group and 3 reported in the placebo group.

  • 29

    Nov

ACOR Acorda Therapeutics
$21.30

0.05 (0.24%)

03/30/16
GSCO
03/30/16
DOWNGRADE
Target $10
GSCO
Neutral
Dimension Therapeutics downgraded to Neutral from Buy at Goldman
Goldman Sachs analyst Salveen Richter downgraded Dimension Therapeutics (DMTX) to Neutral saying other names in the sector offer better near-term opportunities. The analyst views Dimension as well-positioned in the gene therapy space, however. He lowered his price target for the shares to $10 from $12. Richter this morning also initiated SAGE Therapeutics (SAGE) with a Buy rating and Acorda Therapeutics (ACOR) with a Sell rating.
03/30/16
03/30/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Intercept (ICPT) initiated with an Outperform and a Neutral at Credit Suisse and Goldman, respectively. Goldman Sachs analyst Salveen Richter said investor expectations into the April 7 FDA panel for obeticholic acid in primary biliary cholangitis appear high. 2. Acorda Therapeutics (ACOR) initiated with a Sell at Goldman by analyst Salveen Richter, who said Acorda's lead product Ampyra is close to fully realizing its commercial opportunity and that intellectual property threats will present an overhang on the shares. 3. SAGE Therapeutics (SAGE) initiated with a Buy at Goldman due to the belief that the company is a key player in acute central nervous system disorders. 4. Rio Tinto (RIO) initiated with a Buy at Argus. 5. Square (SQ) initiated with a Buy at Mizuho. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/04/16
LEER
10/04/16
INITIATION
Target $25
LEER
Market Perform
Acorda Therapeutics reinstated with a Market Perform at Leerink
Leerink analyst Paul Matteis resumed coverage of Acorda Therapeutics with a Market Perform rating and $25 price target.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).

TODAY'S FREE FLY STORIES

CHDN

Churchill Downs

$172.00

2.65 (1.56%)

11:01
04/27/17
04/27
11:01
04/27/17
11:01
Recommendations
Churchill Downs analyst commentary  »

Churchill Downs price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

11:01
04/27/17
04/27
11:01
04/27/17
11:01
General news
Kansas City Fed Manufacturing Index Level data reported »

April Kansas City Fed…

XOP

SPDR Oil Exploration and Production Fund

$34.82

-1.055 (-2.94%)

11:01
04/27/17
04/27
11:01
04/27/17
11:01
Options
Notable option block in SPDR Oil Exploration and Production ETF »

Notable option block in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:00
04/27/17
04/27
11:00
04/27/17
11:00
General news
Treasury Action: Treasury bulls are getting some traction »

Treasury Action: Treasury…

VIVO

Meridian Bioscience

$14.20

0.2 (1.43%)

10:59
04/27/17
04/27
10:59
04/27/17
10:59
Recommendations
Meridian Bioscience analyst commentary  »

Raymond James…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

DISH

Dish

$63.30

0.76 (1.22%)

, S

Sprint

$8.99

0.075 (0.84%)

10:56
04/27/17
04/27
10:56
04/27/17
10:56
Hot Stocks
Barclays upgrades Dish on potential for deal with carriers »

The shares of Dish (DISH)…

DISH

Dish

$63.30

0.76 (1.22%)

S

Sprint

$8.99

0.075 (0.84%)

TMUS

T-Mobile

$67.58

0.23 (0.34%)

T

AT&T

$40.31

-0.13 (-0.32%)

VZ

Verizon

$47.03

-0.3299 (-0.70%)

STRP

Straight Path

$131.94

1.67 (1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 01

    May

  • 03

    May

  • 09

    May

  • 16

    May

  • 17

    May

10:55
04/27/17
04/27
10:55
04/27/17
10:55
General news
Treasury Option Action: call positioning in the 10-year »

Treasury Option Action:…

KKR

KKR

$18.85

1.075 (6.05%)

10:53
04/27/17
04/27
10:53
04/27/17
10:53
Hot Stocks
KKR 'welcomes' ValueAct investment, Reuters reports »

KKR has held talks with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

DCM

NTT DoCoMo

$23.87

0.68 (2.93%)

10:51
04/27/17
04/27
10:51
04/27/17
10:51
Downgrade
NTT DoCoMo rating change  »

NTT DoCoMo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INFN

Infinera

$9.98

-0.16 (-1.58%)

10:51
04/27/17
04/27
10:51
04/27/17
10:51
Options
Opening interest in Infinera June calls ahead of earnings »

Opening interest in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 09

    May

JNJ

Johnson & Johnson

$123.52

0.01 (0.01%)

10:49
04/27/17
04/27
10:49
04/27/17
10:49
Hot Stocks
Johnson & Johnson raises dividend 5% to 84c per share »

Johnson & Johns…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 05

    May

  • 06

    Jun

FB

Facebook

$146.56

0.07 (0.05%)

, GOOG

Alphabet

$871.73

-0.57 (-0.07%)

10:49
04/27/17
04/27
10:49
04/27/17
10:49
Periodicals
Facebook, Google defrauded in $100M payment scam, Fortune says »

Facebook (FB) and Google…

FB

Facebook

$146.56

0.07 (0.05%)

GOOG

Alphabet

$871.73

-0.57 (-0.07%)

GOOGL

Alphabet Class A

$889.14

0.3 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 03

    May

  • 08

    May

  • 16

    May

  • 22

    May

MSFT

Microsoft

$67.83

-0.09 (-0.13%)

, CASY

Casey's General Stores

$114.17

0.47 (0.41%)

10:48
04/27/17
04/27
10:48
04/27/17
10:48
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

MSFT

Microsoft

$67.83

-0.09 (-0.13%)

CASY

Casey's General Stores

$114.17

0.47 (0.41%)

SXL

Sunoco Logistics

$23.78

-0.49 (-2.02%)

BTU

Peabody Energy

$26.57

0.04 (0.15%)

DXCM

Dexcom

$75.68

0.74 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 02

    May

  • 04

    May

  • 09

    May

  • 23

    May

LLY

Eli Lilly

$81.29

0.33 (0.41%)

, AAL

American Airlines

$46.40

-0.21 (-0.45%)

10:48
04/27/17
04/27
10:48
04/27/17
10:48
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

LLY

Eli Lilly

$81.29

0.33 (0.41%)

AAL

American Airlines

$46.40

-0.21 (-0.45%)

BWLD

Buffalo Wild Wings

$162.40

-0.4 (-0.25%)

WYN

Wyndham

$99.38

-1.16 (-1.15%)

RBS

RBS

$6.53

0.035 (0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 04

    May

  • 07

    May

  • 31

    May

CSCO

Cisco

$33.40

-0.02 (-0.06%)

, MCD

McDonald's

$142.18

1.335 (0.95%)

10:48
04/27/17
04/27
10:48
04/27/17
10:48
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…click here.

CSCO

Cisco

$33.40

-0.02 (-0.06%)

MCD

McDonald's

$142.18

1.335 (0.95%)

AXP

American Express

$80.41

-0.11 (-0.14%)

PYPL

PayPal

$44.41

-0.3 (-0.67%)

DISH

Dish

$63.30

0.76 (1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 01

    May

  • 01

    May

  • 31

    May

  • 12

    Jun

  • 20

    Jun

  • 21

    Jun

  • 22

    Jun

  • 22

    Jun

DSPG

DSP Group

$12.40

0.35 (2.90%)

10:45
04/27/17
04/27
10:45
04/27/17
10:45
Hot Stocks
DSP Group moves up after forecasting sequential increase in Q2 revenue »

Shares of DSP Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 01

    May

  • 02

    May

  • 03

    May

  • 04

    May

  • 09

    May

  • 15

    May

  • 15

    May

10:45
04/27/17
04/27
10:45
04/27/17
10:45
General news
Breaking General news story  »

6-Month Bill Announcement…

10:45
04/27/17
04/27
10:45
04/27/17
10:45
General news
Breaking General news story  »

3-Month Bill Announcement…

SNCR

Synchronoss

$24.62

-0.02 (-0.08%)

10:42
04/27/17
04/27
10:42
04/27/17
10:42
Downgrade
Synchronoss rating change  »

JPMorgan downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

CMCSA

Comcast

$38.79

0.3 (0.78%)

10:41
04/27/17
04/27
10:41
04/27/17
10:41
Options
Large call spread in Comcast as shares rally on earnings »

Large call spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

10:35
04/27/17
04/27
10:35
04/27/17
10:35
General news
Today's U.S. reports »

Today's U.S. reports…

RBS

RBS

$6.55

0.06 (0.92%)

10:31
04/27/17
04/27
10:31
04/27/17
10:31
Options
Pre-earnings call write in Royal Bank of Scotland »

Pre-earnings call write…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:30
04/27/17
04/27
10:30
04/27/17
10:30
General news
EIA natural gas storage change for week ending April 21 »

Gas inventories 74 Bcf…

CHKP

Check Point

$104.22

-1.14 (-1.08%)

, CUDA

Barracuda

$20.40

0.265 (1.32%)

10:28
04/27/17
04/27
10:28
04/27/17
10:28
Hot Stocks
Check Point Q1 results beat expectations as company backs FY17 outlook »

Shares of Check Point…

CHKP

Check Point

$104.22

-1.14 (-1.08%)

CUDA

Barracuda

$20.40

0.265 (1.32%)

IMPV

Imperva

$43.25

-0.25 (-0.57%)

FFIV

F5 Networks

$137.30

-0.89 (-0.64%)

SYMC

Symantec

FTNT

Fortinet

$39.90

-0.37 (-0.92%)

FEYE

FireEye

$12.56

-0.1 (-0.79%)

PANW

Palo Alto Networks

$110.33

1.06 (0.97%)

PFPT

Proofpoint

$77.46

-1.19 (-1.51%)

QLYS

Qualys

$37.90

-0.15 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 02

    May

  • 02

    May

  • 04

    May

  • 08

    May

  • 09

    May

  • 10

    May

  • 08

    Jun

  • 08

    Jun

  • 12

    Jun

DAL

Delta Air Lines

$45.25

-1.125 (-2.43%)

10:26
04/27/17
04/27
10:26
04/27/17
10:26
Options
Delta Air Lines call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.